Joseph Stringer
Stock Analyst at Needham
(2.07)
# 2,789
Out of 4,754 analysts
300
Total ratings
33.33%
Success rate
-4.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LXRX Lexicon Pharmaceuticals | Reiterates: Hold | n/a | $0.29 | - | 12 | Mar 3, 2025 | |
| VIR Vir Biotechnology | Reiterates: Buy | $19 | $7.92 | +139.90% | 16 | Feb 27, 2025 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Buy | $64 | $52.40 | +22.14% | 21 | Feb 27, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $140 | $72.10 | +94.17% | 15 | Feb 26, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Buy | $320 | $243.53 | +31.40% | 19 | Feb 26, 2025 | |
| IONS Ionis Pharmaceuticals | Reiterates: Buy | $60 | $32.60 | +84.05% | 18 | Feb 20, 2025 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $22 | $7.40 | +197.30% | 20 | Feb 18, 2025 | |
| PLRX Pliant Therapeutics | Reiterates: Buy | $10 | $1.38 | +624.64% | 16 | Feb 14, 2025 | |
| GILD Gilead Sciences | Reiterates: Hold | n/a | $115.99 | - | 4 | Feb 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Hold | n/a | $483.31 | - | 5 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $5.21 | +437.43% | 47 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $2.39 | +569.46% | 17 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $29.22 | +105.34% | 15 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $30.27 | - | 8 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $60 | $24.06 | +149.38% | 19 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $1.09 | +2,010.09% | 16 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $23.05 | +8.46% | 8 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.63 | - | 16 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $18.16 | +103.74% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $9.15 | +96.72% | 2 | Aug 24, 2021 |
Lexicon Pharmaceuticals
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $0.29
Upside: -
Vir Biotechnology
Feb 27, 2025
Reiterates: Buy
Price Target: $19
Current: $7.92
Upside: +139.90%
Rhythm Pharmaceuticals
Feb 27, 2025
Reiterates: Buy
Price Target: $64
Current: $52.40
Upside: +22.14%
Vaxcyte
Feb 26, 2025
Reiterates: Buy
Price Target: $140
Current: $72.10
Upside: +94.17%
Alnylam Pharmaceuticals
Feb 26, 2025
Reiterates: Buy
Price Target: $320
Current: $243.53
Upside: +31.40%
Ionis Pharmaceuticals
Feb 20, 2025
Reiterates: Buy
Price Target: $60
Current: $32.60
Upside: +84.05%
Stoke Therapeutics
Feb 18, 2025
Reiterates: Buy
Price Target: $22
Current: $7.40
Upside: +197.30%
Pliant Therapeutics
Feb 14, 2025
Reiterates: Buy
Price Target: $10
Current: $1.38
Upside: +624.64%
Gilead Sciences
Feb 12, 2025
Reiterates: Hold
Price Target: n/a
Current: $115.99
Upside: -
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Hold
Price Target: n/a
Current: $483.31
Upside: -
Jan 10, 2025
Reiterates: Buy
Price Target: $28
Current: $5.21
Upside: +437.43%
Nov 15, 2024
Reiterates: Buy
Price Target: $16
Current: $2.39
Upside: +569.46%
Nov 13, 2024
Reiterates: Buy
Price Target: $60
Current: $29.22
Upside: +105.34%
Nov 8, 2024
Reiterates: Hold
Price Target: n/a
Current: $30.27
Upside: -
Nov 6, 2024
Maintains: Buy
Price Target: $85 → $60
Current: $24.06
Upside: +149.38%
Nov 6, 2024
Reiterates: Buy
Price Target: $23
Current: $1.09
Upside: +2,010.09%
Aug 14, 2024
Reiterates: Buy
Price Target: $25
Current: $23.05
Upside: +8.46%
Jun 13, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.63
Upside: -
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $18.16
Upside: +103.74%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $9.15
Upside: +96.72%